The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chakhava V.O.

GNTs sotsial'noĭ i sudebnoĭ psikhiatrii im. V.P. Serbskogo, Moskva

Budtueva F.S.

GNTs sotsial'noĭ i sudebnoĭ psikhiatrii im. V.P. Serbskogo, Moskva

Borukaev R.R.

GNTs sotsial'noĭ i sudebnoĭ psikhiatrii im. V.P. Serbskogo, Moskva

Efficacy of adepress (paroxetin) in generalized anxiety disorder

Authors:

Chakhava V.O., Budtueva F.S., Borukaev R.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(8): 25‑29

Read: 7220 times

Download PDF (RU)
Contact the author
Table of contents

EFFICACY OF ADEPRESS (PAROXETIN) IN GENERALIZED ANXIETY DISORDER
EFFICACY OF ADEPRESS (PAROXETIN) IN GENERALIZED ANXIETY DISORDER

To cite this article:

Chakhava VO, Budtueva FS, Borukaev RR. Efficacy of adepress (paroxetin) in generalized anxiety disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(8):25‑29. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Como­rbid anxiety diso­rders in patients with neurological pathology: current state of the problem and the role of etifoxine in treatment stra­tegy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):126-136
Clinical and epidemiological indi­cators of stroke during the COVID-19 pandemic and in the post-COVID period in the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):5-11
Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77
Unre­solved problem: Chemotherapy-Induced Peri­pheral Neuropathy. P.A. Herzen Journal of Onco­logy. 2024;(5):76-81
Quality asse­ssment of health care deli­very to patients with sexually transmitted infe­ctions in dermatovenereological institutions of Moscow acco­rding to medi­cal reco­rds analysis. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):503-509
Psoriasis in pregnant women. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):517-524
Tube­rculous otitis media in an adolescent. Clinical case. Russian Bulletin of Otorhinolaryngology. 2024;(5):63-66
Comparative analysis of the resu­lts of treatment of gastric polyps by methods of loop electroexcision, laser and endo­scopic poly­pectomy with aspi­ration capture. Endo­scopic Surgery. 2024;(6):24-30
Black Acanthosis: Diagnosis and Treatment Issues. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):709-712
Resu­lts of the All-Russian consensus conference on complications in bariatric surgery. Endo­scopic Surgery. 2025;(1):15-24
Abstract:

The aim of the study was to evaluate efficacy of adepress (paroxetin) in different clinical variants of generalized anxiety disorder (GAD). Adepress was used as a monotherapy during 42 days. Patient's state was assessed using Hamilton anxiety scale (HAM-A) at baseline and every week thereafter. The study included 49 patients aged 36,2±8,2 years. Patients were stratified into two groups according to the predominance of somatic (24 cases) or cognitive (21 cases) anxiety. The efficacy of adepress was shown both in a separate GAD and in a GAD with comorbid psychopathology. The effect of the drug was seen in patients with somatic anxiety after 3-4 weeks and in patients with cognitive anxiety after 3-6 weeks.

Keywords:

generalized anxiety disorder
somatic anxiety
cognitive anxiety
treatment
adepress (paroxetin)

Authors:

Chakhava V.O.

GNTs sotsial'noĭ i sudebnoĭ psikhiatrii im. V.P. Serbskogo, Moskva

Budtueva F.S.

GNTs sotsial'noĭ i sudebnoĭ psikhiatrii im. V.P. Serbskogo, Moskva

Borukaev R.R.

GNTs sotsial'noĭ i sudebnoĭ psikhiatrii im. V.P. Serbskogo, Moskva

Close metadata

References:

  1. Avedisova A.S. Venlafaksin (velaksin): rezul'taty mezhdunarodnykh issledovanii antidepressanta III pokoleniya. Consilium Medicum 2006;11:14:3.
  2. Aleksandrovskii Yu.A. Pogranichnye psikhicheskie rasstroistva. 2-e izd. Rostov-na-Donu: Feniks 1997;579.
  3. Akhapkin R.V. Primenenie preparata plizil (paroksetin) v psikhiatricheskoi praktike. Psikhiat i psikhofarmakoter ;10:3:61-66.
  4. Less Yu.E. Generalizovannoe trevozhnoe rasstroistvo: tipologiya i komorbidnye sostoyaniya. Ros psikhiat zhurn 2008;2:40-45.
  5. Mosolov S.N. Klinicheskoe primenenie sovremennykh antidepressantov. St-Peterburg 1995.
  6. Mosolov S.N. Osnovy psikhofarmakoterapii. M 1996.
  7. Morozov P.V. Terapiya depressii i trevozhnykh rasstroistv v sovremennoi psikhiatrii. Psikhiat i psikhofarmakoter 2005;7:3.
  8. Smulevich A.B. Antidepressanty v obshchemeditsinskoi praktike. Consilium Medicum 2002;3-7 (prilozhenie).
  9. Chakhava V.O., Less Yu.E., Malygin Ya.V. Effektivnost' preparata Reksetin u bol'nykh s generalizovannym trevozhnym rasstroistvom. Ros med zhurn 2007;15:24:305:1860-1866.
  10. Chakhava V.O., Less E.Yu., Borukaev R.R. Effektivnost' primeneniya venlafaksina pri trevozhnoi depressii i generalizovannom trevozhnom rasstroistve. Ros psikhiat zhurn 2007;2:85-89.
  11. Brawman-Mintzer O. Pharmacologic treatment of generalized anxiety disorder. Psychiatr Clin North Am 2001;24:119-137.
  12. Ballenger J.C., Davidson J.R.T., Lecrubier Y. et al.  Consensus statement on generalized anxiety disorder from the International Consensus group on Depression and anxiety. J Clin Physiat 2001;62:Suppl 11:53-58.
  13. Gelenberg A.J., Lydiard R.B., Rudolph R.L. et al. Efficacy of Venlafaxine Extended-Release Capsules in Nondepressed Outpatients With Generalized Anxiety Disorder. JAMA 2000;283:3082-3088.
  14. Hedges D.W., Reimherr F.W., Strong R.E. et al. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull 1996;32:4:671-676.
  15. Hoehn-Saric R., McLeod D.R., Zimmerli W.D. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiat 1988;49:293-301.
  16. Klein D.F. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964;5:397-408.
  17. Raj A., Sheehan D. Antidepressants in the treatment of Generalized Anxiety Disorder. In: Generalized Anxiety Disorder. Eds. D. Nutt, K. Rickels, D. Stein. Martin Dunitz Ltd 2002;137-152.
  18. Rickels K., Downing R., Schweizer E., Hassman H. Antidepressants for the treatment of generalized anxiety disorder. Arch Gen Psychiat 1993;50:884-895.
  19. Rocca P., Fonzo P., Scotta M. et al.  Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiat Scand 1997;95:444-450.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.